During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide
These include optimal nutrition, exercise, sleep habits, hormone optimization, stress management, sense of purpose/social connections, medications, and avoidance of harmful behaviors
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
The creation of assays that accurately reflect in vivo conditions for antibody effector activity is perhaps even more difficult than for neutralization activity
